June 2013
Volume 54, Issue 15
ARVO Annual Meeting Abstract  |   June 2013
Efficacy of long-term treatment with diquafosol sodium for dry eye due to laser in situ keratomileusis
Author Affiliations & Notes
  • Ryohei Nejima
    Miyata Eye Hospital, Miyakonojyo, Japan
  • Yosai Mori
    Miyata Eye Hospital, Miyakonojyo, Japan
  • Ayami Masuda
    Miyata Eye Hospital, Miyakonojyo, Japan
  • Yoko Maruyama
    Miyata Eye Hospital, Miyakonojyo, Japan
  • Keiichiro Minami
    Miyata Eye Hospital, Miyakonojyo, Japan
  • Kazunori Miyata
    Miyata Eye Hospital, Miyakonojyo, Japan
  • Footnotes
    Commercial Relationships Ryohei Nejima, None; Yosai Mori, None; Ayami Masuda, None; Yoko Maruyama, None; Keiichiro Minami, None; Kazunori Miyata, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 6037. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Ryohei Nejima, Yosai Mori, Ayami Masuda, Yoko Maruyama, Keiichiro Minami, Kazunori Miyata; Efficacy of long-term treatment with diquafosol sodium for dry eye due to laser in situ keratomileusis. Invest. Ophthalmol. Vis. Sci. 2013;54(15):6037.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: To evaluate the efficacy of long-term treatment with 3% diquafosol solution (DQS), that is a P2Y2 receptor agonist facilitating mucin secretion from the conjunctival goblet cells, for chronic dry eye after laser in situ keratomileusis (LASIK).

Methods: This prospective clinical study comprising 18 eyes (9 patients) to which DQS was additionally instilled 4 times a day. Tear secretin, tear break-up time (BUT), superficial punctate keratitis (SPK), and conjunctivitis sicca were examined before and at 1,3, 6, 9 and 12 months after treatment. Tear secretin was examined with the Schirmer test with anesthesia before and after the DQS treatment. And also, Tear breakup time (BUT), fluorescein stain, and lissamine green stain were examined before and after the DQS treatment. A questionnaire survey regarding 14 symptoms was also assessed before treatment and at 12 months after. The changes in BUT and staining scores between before and after DQS treatment were examined using Kruskal-Wallis test following the Steel-Dwass multiple comparison. Changes in the tear secretion and each symptom in the questionnaire were compared using the Wilcoxon signed-ranks test. P<0.05 was considered significant.

Results: DQS treatment, tear secretin did not change, thought BUT significantly increased after 1,3,6,9 and 12 months . SPK improved at all evaluation points. Lissamine green score improved after 6,9 and 12 months. Of the 14 items on the symptoms questionnaire, dryness, discomfort, grittiness were improved.

Conclusions: DQS was long-term effective in improving ocular surface disorder and dry eye symptoms after LASIK. The mechanism of the improvement was assumed to be improved levels of mucin and tears in the tear film. DQS is another therapy for addressing LASIK-associated dry eye syndrome.

Keywords: 486 cornea: tears/tear film/dry eye • 485 cornea: surface mucins • 479 cornea: clinical science  

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.